Drug discovery Startups

Notable Labs operates a personalized drug discovery platform that tests combinations of FDA-approved drugs against a patient's own cancer cells to identify treatment options, focusing initially on relapsed and refractory blood cancer. It runs a highly automated lab with custom software and works with relapsed/refractory cancer patients as well as pharma and biotech partners.

11 investors

ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

10 investors

Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

10 investors

Abalone Bio develops activating antibodies (agonists) targeting hard-to-drug receptors such as G-protein coupled receptors, using engineered cells to measure antibody pharmacological activity at high throughput combined with machine learning. Its initial focus is cell-specific antibody drugs for obesity and metabolic disease aimed at avoiding the GI side effects associated with GLP-1 therapies.

9 investors

EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

9 investors

Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.

9 investors

Ångström AI develops AI-powered physics simulations for pharmaceutical drug discovery, computing molecular properties like solubility, lipophilicity, and crystal structure stability to replace traditional lab experiments. The platform uses machine learning interatomic potentials and free energy calculations to accelerate and derisk solid form development for pharma companies.

8 investors

GEn1E Lifesciences is a clinical-stage drug development company that uses an AI platform to design immunomodulatory therapies for rare and inflammatory diseases that lack effective treatments. Its pipeline includes 21+ immunomodulators, with a lead program targeting ARDS.

8 investors

General Proximity develops proximity-based technologies for drug discovery and development. The company employs scientists from leading academic and pharmaceutical institutions.

8 investors

Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.

7 investors

Numerion Labs develops machine learning algorithms for drug discovery, combining computational chemistry, structural biology, and medicinal chemistry. It builds AI-driven platforms aimed at accelerating the identification of new medicines.

7 investors

Synvivia develops chemical control technology over cell behavior to optimize the biomanufacturing of high-value biopharmaceutical products. It operates in the synthetic biology and drug discovery space.

7 investors

Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.

7 investors

Arpeggio Bio is a pharmaceutical company that uses AI and high-throughput RNA-sequencing to develop drugs targeting transcription factors, including historically "undruggable" proteins such as NRF2, TEAD, and GPX4. Its lead program targets IO-resistant melanoma, and it has worked on rare disease and inflammation programs through partnerships.

6 investors

Sequence Bio works on drug target discovery, using the Newfoundland founder effect to identify genetic signals of disease and improve the success rate of drug development.

6 investors

Algen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.

5 investors

Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.

5 investors

Serna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.

5 investors

Forcyte Biotechnologies develops drug screening tools that measure cell contractility to identify therapeutic candidates for diseases driven by abnormal cellular force generation, such as asthma, fibrosis, and hypertension.

4 investors

Harmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.

4 investors

Anto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.

3 investors

Lavo Life Sciences offers computational molecular simulations to pharmaceutical companies, helping them optimize drug formulations, reduce experimental costs, and accelerate the path to clinical trials and regulatory approval.

3 investors

LEAH Labs develops CAR-T cell therapy for pets, starting with dogs with B cell lymphoma, using a virus-free gene editing platform to produce engineered cell therapy doses at low cost. It targets general practice veterinarians across the USA, with a longer-term goal of extending its therapies to humans.

3 investors

AtlasDiscovery develops foundation models of patient drug response trained on pre-clinical and clinical data to improve drug trial design and success rates. The company serves pharmaceutical and biotech firms by predicting human drug responses and enabling drug rescue and development in the biotech industry.

2 investors